Royalty Pharma (RPRX) Income towards Parent Company (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Income towards Parent Company data on file, last reported at $468.3 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 7.79% year-over-year to $468.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (down 23.2% YoY), and the FY2025 full-year result was $1.3 billion, changed 0.5% from the prior year.
• Income towards Parent Company improved to $468.3 million in Q1 2026, from $355.9 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $806.4 million in Q3 2024 to a low of -$610.0 million in Q4 2022.
• A 5-year average of $297.3 million and a median of $351.3 million in 2023 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company slumped 1236.61% in 2022 and soared 10266.93% in 2025, its largest moves.
• Tracing RPRX's Income towards Parent Company over 5 years: stood at -$610.0 million in 2022, then soared by 217.63% to $717.6 million in 2023, then slumped by 53.41% to $334.4 million in 2024, then grew by 6.45% to $355.9 million in 2025, then surged by 31.56% to $468.3 million in 2026.
• Business Quant data shows RPRX's Income towards Parent Company at $468.3 million in Q1 2026, $355.9 million in Q4 2025, and $444.2 million in Q3 2025.